Modulatory effects of vasoactive intestinal peptide on intestinal mucosal immunity and microbial community of weaned piglets challenged by an enterotoxigenic Escherichia coli (K88)

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Xu, Chunlan ^a   Wang, Youming ^b   Sun, Rui ^a   Qiao, Xiangjin ^a   Shang, Xiaoya ^a   Niu, Weining ^a  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; OCCLUDIN; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; CYTOKINE; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFECT; DRUG RESPONSE; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; INTESTINE MUCOSA; MICROBIAL COMMUNITY; NONHUMAN; PIGLET; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPECIES DIVERSITY; SPECIES RICHNESS; ANIMAL; BLOOD; CECUM; COLON; IMMUNOLOGY; INTESTINE; MALE; METABOLISM; MICROBIOLOGY; MICROFLORA; MUCOSAL IMMUNITY; PATHOLOGY; PHYSIOLOGY; SWINE; WEANING;

ANIMALS; CECUM; COLON; CYTOKINES; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; IMMUNITY, MUCOSAL; IMMUNOLOGIC FACTORS; INTESTINES; MALE; MICROBIOTA; OCCLUDIN; SWINE; VASOACTIVE INTESTINAL PEPTIDE; WEANING;

EID: 84905484325     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104183     Document Type: Article

References (78)

1. Stokes CR, Bailey M, Haverson K, Harris C, Jones P, et al. (2004) Postnatal development of intestinal immune system in piglets: implications for the process of weaning. Anim Res 53: 325-334. (Pubitemid 39583898)
2. Fairbrother JM, Nadeau E, Gyles CL (2005) Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies. Anim Health Res Rev 6: 17-39.
3. Konstantinov SR, Favier CF, Zhu WY, Williams BA, Klub J, et al. (2004) Microbial diversity studies of the porcine gastrointestinal ecosystem during weaning transition. Anim Res 53: 317-24. (Pubitemid 39583897)
4. Bailey M, Haverson K, Inman C, Harris C, Jones P, et al. (2005) The development of the mucosal immune system pre- and post-weaning: balancing regulatory and effector function. Proc Nutr Soc 64: 451-457. (Pubitemid 41705444)
5. Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313-323.
6. Keita AV, Soderholm JD (2010) The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenerol Motil 22: 718-733.
7. Gomariz RP, Gutierrez-Canas I, Arranz A, Carrion M, Juarranz Y, et al. (2010) Peptides targeting toll-like receptor signaling pathway for novel immune therapeutics. Current Pharmaceutical Design 16: 1063-1080.
8. Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, et al. (2007) Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 28: 1833-1846. (Pubitemid 47361418)
9. Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21: 619-670. (Pubitemid 32113287)
10. Kojima M, Ito T, Oono T, Hisano T, Igarashi H, et al. (2005) VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 30: 62-70. (Pubitemid 40070628)
11. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J (2000) Antiinflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30: 3236-46.
12. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. NatMed 7: 563-568. (Pubitemid 32448323)
13. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, et al. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124: 961-971. (Pubitemid 36389799)
14. Bik W, Wolinska-Witort E, Chmielowska M, Baranowska-Bik A, Rusiecka-Kuczalek E, et al. (2004) Vasoactive intestinal peptide can modulate immune and endocrine responses during lipopolysaccharide-induced acute inflammation. Neuroimmunomodulation 11: 358-364. (Pubitemid 39370443)
15. Ei-Karim IA, Linden GJ, Orr DF, Lundy FT (2008) Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol 200: 11-16.
16. Campos-Salinas J, Cavazzuti A, O'Valle F, Forte-Lago I, Caro M, et al. (2014) Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens. J. Biol Chem 289: 14583-14599.
17. Liu P, Piao XS, Thacker PA, Zeng ZK, Li PF, et al. (2010) Chito-oligosaccharide reduces diarrhea incidence and attenuates the immune response of weaned pigs challenged with Escherichia coli K88. J Anim Sci. 88: 3871-3879.
18. Kiarie E, Bhandari S, Scott M, Krause DO, Nyachoti CM (2011) Growth performance and gastrointestinal microbial ecology responses of piglets receiving saccharomyces cerevisiae fermentation products after an oral challenge with Escherichia coli (K88). J Anim Sci. 89: 1062-1078.
19. Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martinez C (2008) VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptide. 29: 948-956.
20. Schmidt PT, Eriksen L, Loftager M, Rasmussen TN, Holst JJ (1999) Fast acting nervous regulation of immunoglobulin A secretion from isolated perfused porcine ileum. Gut 45: 679-685. (Pubitemid 29492140)
21. Nyachoti CM, Kiarie E, Bhandari SK, Zhang G, Krause DO (2012) Weaned pig responses to Escherichia coli K88 oral challenge when receiving a lysozyme supplement. J Anim Sci. 90: 252-260.
22. Francis DH, Grange PA, Zeman DH, Baker DR, Sun RG, et al. (1998) Expression of mucin-type glycoprotein K88 receptor strongly correlates with piglet susceptibility to K88 enterotoxigenic Escherichia coli, but adhesion of this bacterium to brush border does not. Infect. Immun. 66: 4050-4055. (Pubitemid 28402670)
23. Gaastra W, de Graaf FK (1982) Host-specific fimbrial adhensins of noninvasive enterotoxigenic Escherichia coli strains. Microbiol Rev 46: 129-161. (Pubitemid 12010544)
24. Owusu-Asiedu A, Nyachoti CM, Marquardt RR (2003) Response of early-weaned pigs to an enterotoxigenic Escherichia coli (K88) challenge when fed diets containing spray-dried porcine plasma or pea protein isolate plus egg yolk antibody, zinc oxide, fumaric acid, or antibiotic. J Anim Sci 81: 1790-1798. (Pubitemid 38572491)
25. Nyachoti CM, Omogbenigun FO, Rademacher M, Blank G (2006) Performance responses and indicators of gastrointestinal health in early-weaned pigs fed low-protein amino acid-supplemented diets. J Anim Sci 84: 125-134. (Pubitemid 44405735)
26. Groschwitz KR, Hogan SP (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124: 3-20.
27. Kim JC, Hansen CF, Mullan BP, Pluske JR (2012) Nutrition and pathology of weaner pigs: Nutrional strategies to support barrier function in the gastrointestinal tract. Anim Feed Sci Technol 173: 3-16.
28. Ai-Sadi R, Khatib K, Guo S, Ye D, Yousset M, et al. (2011) Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 300: G1054-G1064.
29. Wong V, Gumbiner BM (1997) A synthetic peptide corresponding to the extracellular domain of occluding perturbs the tight junction permeability barrier. J Cell Biol 136: 399-409. (Pubitemid 27063089)
30. Neunlist M, Toumi F, Oreschkova T, Denis M, Leborgne J, et al. (2003) Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPerigic pathway. Am J Physiol Gastrointest Liver Physiol 285: G1028-G1036. (Pubitemid 37310081)
31. Clarke TB, Francella N, Huegel A, Weiser JN (2011) Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe, 9: 404-414.
32. Conlin VS, Wu X, Nguyen C, Dai C, Vallance BA, et al. (2009) Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol 297: G735-G750.
33. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. (Pubitemid 47123518)
34. Corthesy B (2013) Multi-faceted functions of secretory IgA at mucosal surfaces. Front. Immunol. 4: 1-11.
35. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162: 1707-1716. (Pubitemid 29307049)
36. Nusrat A, Turner JR, Madara JL (2000) Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 279: G851-G857.
37. Capaldo CT, Nusrat A (2009) Cytokine regulation of tight junctions. Biochim Biophys Acta 1788: 864-871.
38. Pie S, Lalles JP, Blazy F, Laffitte J, Seve B, et al. (2004) Weaning is associated with an upregulation of expression of inflammatory cytokines in the intestine of piglets. J Nutrition 134: 641-647. (Pubitemid 38298510)
39. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, et al. (1999) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J Immunol 162: 1200-1205. (Pubitemid 29035454)
40. Kovsca Janjatovic A, Valpotic H, Kezic D, Lackovic G, Gregorovic G, et al. (2012) Secretion of immunomodulating neuropeptides (VIP, SP) and nitric oxide synthase in porcine small intestine during postnatal development. Eur J Histochem 56: e30.
41. Prasse A, Zissel G, Lutzen N, Schupp J, Schmiedlin R, et al. (2010) Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 182: 540-548.
42. Chorny A, Delgado M (2008) Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 172: 1297-1302. (Pubitemid 351671542)
43. Delgado M, Pozo D, Ganea D (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-290. (Pubitemid 38720831)
44. Gonzale-Rey E, Chorny A, Delgado M (2007) Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 7: 52-63. (Pubitemid 46020827)
45. Delgado M, Ganea D (2001) Gutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 166: 2907-2912. (Pubitemid 33117283)
46. Kimata H, Fujimoto M (1994) Vasoactive intestinal peptide specifically induces human IgA1 and IgA2 production. Eur J Immunol 24: 2262-2265. (Pubitemid 24276566)
47. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, et al. (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 80: 16-24. (Pubitemid 34143404)
48. De la Fuente M, Delgado M, Gomariz RP (1996) VIP modulation of immune cell function. Adv Neuroimmunol 6: 75-91. (Pubitemid 26185013)
49. Delgado M, De la Fuente M, Martinez C, Gomariz RP (1995) Pituitary adenylate cyclaseactivating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. J Neuroimmunol 62: 137-146.
50. Roselli M, Finamore A, Britti MS, Bosi P, Oswald I, et al (2005) Alternatives to in-feed antibiotics in pigs: Evaluation of probiotics, zinc or organic acids as protective agents for the intestinal mucosa. A comparison of in vitro and in vivo results. Anim Res 54: 203-218. (Pubitemid 41323251)
51. Konstantinov SR, Favier CF, Zhu WY, Williams BA, Klüb J, et al. (2004) Microbial diversity studies of the porcine gastrointestinal ecosystem during weaning transition. Anim Res 53: 317-324. (Pubitemid 39583897)
52. Augustyniak D, Nowak, Lundy FT (2012) Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr. Protein Pept Sci. 13: 723-738.
53. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 52: 269-324. (Pubitemid 30368434)
54. Delgado M, Anderson P, Garcia-Salcedo JA, Caro M, Gonzalez-Rey E (2009) Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ. 16: 406-416.
55. Brogden KA, Guthmiller JM, Salzet M, Zasloff M (2005) The nervous system and innate immunity: the neuropeptide connection. Nat Immunol 6: 558-564. (Pubitemid 41710725)
56. Leser TD, Amernuvor JZ, Jensen TK, Lindecrona RH, Boye M, et al. (2004) Culture-independent analysis of gut bacteria: the pig gastrointestinal tract microbiota revisited. Appl Environ Microbiol 68, 673-690. (Pubitemid 34113056)
57. Guo X, Xia X, Tang R, Zhou J, Zhao H, et al. (2008) Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47: 367-373.
58. Goyal RK, Hirano I (1996) The enteric nervous system. N Engl J Med 334: 1106-1115. (Pubitemid 26120190)
59. Mccabe RD, Dharmsathaphorn K (1988) Mechanism of VIP-stimulated chloride secretion by intestinal epithelial cells. Annals of the New York Academy of Sciences 527: 326-345.
60. Laburthe M, Auqeron C, Rouyer-Fessard C, Roumaqnac I, Maoret JJ, et al. (1989) Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E. Am J Physiol 256: G443-G450.
61. Mourad FH, Nassar CF (2000) Effect of vasoactive intestinal polypeptide (VIP) antagonism on rat jejuna fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut 47: 382-386.
62. Lallès JP, Bosi P, Janczyk P, Koopmans SJ, Torrallardona D (2009) Impact of bioactive substances on the gastrointestinal tract and performance of weaned piglets: a review. Animal 3: 1625-1643.
63. Guzman JR, Conlin VS, Jobin C (2013) Diet, microbiome, and the intestinal epithelium: an essential triumvirate? BioMed Res Intern. 2013: 1-12.
64. Westendorf AM, Fleissner D, Hansen W, Buer J (2010) T cells, dendritic cells and epithelial cells in intestinal homeostasis. Int J Med Microbiol 300: 11-18.
65. Alvarez S, Villena J, Tohno M, Salva S, Kitazawa H (2009) Modulation of innate immunity by lactic acid bacteria: impact on host response to infections. Curr Res Immunol 3: 87-126.
66. Kitazawa H, Tohno M, Shimosato T, Saito T (2008) Development of molecular immunoassay system for probiotics via toll-like receptors based on food immunology. Anim Sci 79: 11-21.
67. Long KZ, Rosado JL, Santos JI, Haas M, Ai Mamun A, et al. (2010) Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun 78: 1221-1228.
68. Gomariz RP, Arranz A, Juarranz Y, Gutierrez-Canas I, Garcia-Gomez M, et al. (2007) Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 28: 1825-1832. (Pubitemid 47361437)
69. Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martinez C (2008) VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29: 948-956.
70. Gonzalez-Rey E, Chorny A, Delgado M (2007) Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev 7: 52-63. (Pubitemid 46020827)
71. Dokladny K, Lobb R, Wharton W, Ma TY, Moseley PL (2010) LPS-induced cytokine levels are repressed by elevated expression of HSP70 in rats: possible role of NF-kappa B. Cell Stress Chaperones 15: 153-163.
72. Hwang MH, Damte D, Lee JS, Gebru E, Chang ZQ, et al. (2011) Mycoplasma hyopneumoniae induces pro-inflammatory cytokine and nitric oxide production through NF-κB and MAPK pathways in RAW264.7 cells. Vet Res Commun 35: 21-34.
73. Gonzalez-Rey E, Chorny A, Delgado M (2007) Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev 7: 52-63. (Pubitemid 46020827)
74. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, et al. (2005) Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM-and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem 280: 5491-5495. (Pubitemid 40280025)
75. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Carias I, et al. (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7: R1034-1045.
76. Delgado M, Ganea D (2000) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK/MEK4/JNK signaling pathway in LPS-activated macrophages. J Neuroimmunol 110: 97-105.
77. Delgado M, Ganea D (2003) Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem Biophys Res Commun 302: 275-283. (Pubitemid 36397917)
78. Laburthe M, Couvineau A (2002) Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regulaory Peptides. 108: 165-173. (Pubitemid 35239874)